All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The product of this gene belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneous humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. This gene, and also the SSX1 and SSX4 family members, have been involved in t(X;18)(p11.2;q11.2) translocations that are characteristically found in all synovial sarcomas. This translocation results in the fusion of the synovial sarcoma translocation gene on chromosome 18 to one of the SSX genes on chromosome X. The encoded hybrid proteins are likely responsible for transforming activity. Alternative splicing of this gene results in multiple transcript variants. This gene also has an identical duplicate, GeneID: 727837, located about 45 kb downstream in the opposite orientation on chromosome X.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-L107 | Murinized (from Human) anti-SSX2 (KASEKIFYV) T Cell Receptor, pMSGV1 | Human | Murinized (from Human) | KASEKIFYV | HLA-A2 | retroviral vector | ||
TCR-L106Z | Murinized anti-SSX2 (aa41-49) T cell receptor, pCDTCR1 | Human | Murinized (from Human) | KASEKIFYV | HLA-A2 | Lentiviral | ||
TCR-C239Z | Human anti-SSX2 T cell receptor (TCR5), pCDTCR1 | Human | TCR5 | Human | KASEKIFYV | HLA-A*0201 | Lentiviral | |
TCR-C240Z | Murinized anti-SSX2 T cell receptor (TCR5), pCDTCR1 | Human | TCR5 | Murinized | KASEKIFYV | HLA-A*0201 | Lentiviral | |
TCR-L262 | Human anti-SSX-2 T cell receptor, pCDTCR1 | Human | Human | KASEKIFYV | HLA-A2 | Lentiviral | ||
TCR-L263 | Human anti-SSX-2 T cell receptor, pCDTCR1 | Human | Human | KASEKIFYV | HLA-A2 | Lentiviral |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION